Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

462
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
462
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

179
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
179
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

527
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
527
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

257
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
257
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

1.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.4K
Lysosomal Hydrolases01:22

Lysosomal Hydrolases

3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Addressing the needs of nano-rare patients: the n-Lorem experience.

Nucleic acids research·2026
Same author

Long-term outcomes of hyperadrenergic orthostatic hypotension.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Multiple System Atrophy Combined Outcome Assessment (MuSyCA): process, format, and validation plan.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Clinical autonomic research: welcome to 2026.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Setting up an autonomic unit within the neurological department: a position statement of the European Federation of Autonomic Societies.

Clinical autonomic research : official journal of the Clinical Autonomic Research Society·2026
Same author

Types of Pain in Multiple System Atrophy.

Movement disorders : official journal of the Movement Disorder Society·2026

Related Experiment Video

Updated: Jun 24, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K

An update on multiple system atrophy.

Iva Stankovic1, Mechteld Kuijpers2, Horacio Kaufmann2

  • 1Neurology Clinic, University Clinical Center of Serbia, School of Medicine, University of Belgrade, Serbia.

Current Opinion in Neurology
|June 3, 2024
PubMed
Summary
This summary is machine-generated.

New diagnostic criteria and alpha-synuclein biomarkers improve Multiple System Atrophy (MSA) detection. Promising therapies targeting alpha-synuclein are in development to halt disease progression.

More Related Videos

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.6K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K

Related Experiment Videos

Last Updated: Jun 24, 2025

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

11.5K
A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.6K
Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis
07:00

Eye-Tracking Control to Assess Cognitive Functions in Patients with Amyotrophic Lateral Sclerosis

Published on: October 13, 2016

8.2K

Area of Science:

  • Neuroscience
  • Neurology
  • Pathophysiology

Background:

  • Multiple system atrophy (MSA) is a progressive synucleinopathy.
  • Characterized by autonomic failure, parkinsonism, and cerebellar ataxia.

Purpose of the Study:

  • Update on alpha-synuclein's role in MSA.
  • Review new Movement Disorders Society (MDS) diagnostic criteria.
  • Evaluate alpha-synuclein biomarkers and clinical trial readiness for therapies.

Main Methods:

  • Review of current literature on MSA pathophysiology.
  • Analysis of new diagnostic criteria and biomarker utility.
  • Overview of ongoing clinical trials for disease-modifying therapies.

Main Results:

  • Urinary tract infections and oligodendroglial genes implicated in MSA.
  • New criteria improve early diagnosis accuracy.
  • CSF/serum alpha-synuclein, skin phosphorylated deposits, and PET imaging show diagnostic potential.
  • Clinical trials target alpha-synuclein aggregation/expression, stem cells, and gene therapy.

Conclusions:

  • Enhanced diagnostic accuracy with new MSA criteria and biomarkers.
  • Development of promising therapies to address MSA progression.